Readoutin 135d
Innovent Biologics Technology Limited (Shanghai R&D Center) — Febuxostat
Phase 3 primary completion: Tigulixostat (IBI128) vs Febuxostat in Gout.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Gout
Readoutin 135d
Phase 3 primary completion: Tigulixostat (IBI128) vs Febuxostat in Gout.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.